Mawson Infrastructure Group Inc. — Director's Dealing 2020

Dec 31, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wize Pharma, Inc. (WIZP)
CIK: 0001218683
Period of Report: 2020-12-29

Reporting Person: Rimon Gold Assets Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-29	Common Stock	X	400000	—	Acquired	4002925	Direct
2020-12-29	Common Stock	S	3077	—	Disposed	3999848	Direct
2020-12-29	Common Stock	X	3385212	—	Acquired	7385060	Direct
2020-12-29	Common Stock	S	28210	—	Disposed	7356850	Direct
2020-12-29	Common Stock	X	520820	—	Acquired	7877670	Direct
2020-12-29	Common Stock	S	4340	—	Disposed	7873330	Direct
2020-12-29	Common Stock	X	350334	—	Acquired	7522996	Direct
2020-12-29	Common Stock	S	2919	—	Disposed	7520077	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-29	Warrant (right to buy)	$0.16	X	400000	Disposed	2023-10-23	Common Stock (400000)	Direct
2020-12-29	Warrant (right to buy)	$0.27	X	3385212	Disposed	2024-12-12	Common Stock (3385212)	Direct
2020-12-29	Warrant (right to buy)	$0.16	X	520820	Disposed	2021-05-30	Common Stock (520820)	Direct
2020-12-29	Future Investment Rights	$0.27	X	350334	Disposed	2024-12-12	Common Stock (350334)	Direct

Footnotes

F1: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

F2: On December 29, 2020 the reporting person exercised a warrant to purchase 400,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 3,077 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 396,923 shares.

F3: On December 29, 2020 the reporting person exercised a warrant to purchase 3,385,212 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 28,210 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 3,357,002 shares.

F4: On December 29, 2020 the reporting person exercised a warrant to purchase 520,820 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 4,340 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 516,480 shares.

F5: On December 29, 2020 the reporting person exercised a warrant to purchase 350,334 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,919 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,415 shares.

F6: Exercisable five days following the public announcement of positive clinical data results for LO2A.